3 unknown, 1 completed, 1 not yet recruiting, 1 recruiting. 7 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Unknown 3, Completed 1, Not yet recruiting 1, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
Follow SHR3162: new trials by email Literature Review of SHR3162 trials Research Report on SHR3162
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| SNF Platform Study of HR+/ HER2-advanced Breast Cancer PIK3CA inhibitor, AKT inhibitor, Carrelizumab - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 620 | 2022-12-30 | 2024-10-04 |
| A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） Fluzoparib, Apatinib - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2020-07-01 | 2020-12-09 |
| Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer SHR7390, Famitinib, SHR3162 - Breast Cancer, Metastatic Cancer | Phase 2 | Unknown | Fudan University | 319 | 2020-05-01 | 2022-07-26 |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer Fluzoparib, Fluzoparib placebo, mFOLFIRINOX - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 39 | 2020-01-21 | 2024-08-16 |
| A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC SHR3680, SHR3162, SHR3680(Placebo) - Prostate Cancer, Castration-resistant Prostate Cancer | Phase 2 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 20 | 2019-04-08 | 2025-06-24 |
| FUSCC Refractory TNBC Umbrella (FUTURE) Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), anti PD-1 with nab-paclitaxel - Triple-negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 140 | 2018-10-18 | 2022-08-10 |
Breast Neoplasms (2) · Neoplasm Metastasis (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1) · Triple Negative Breast Neoplasms (1)
Fudan University (3) · Jiangsu HengRui Medicine Co., Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Tianjin Medical University Second Hospital (1)
China (6)
Haitao Wang (1) · Xianjun Yu, M.D. (1) · Zhi-Ming Shao (1) · Zhimin U Shao, Professor (1)
PMID 32719455, PMID 33570247, PMID 35105939, PMID 38290515, PMID 39232761